PETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION SERVICES AGREEMENT WITH MWI ANIMAL HEALTH
June 29 2022 - 12:48PM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo"), an
emerging biomedical device company focused on the commercialization
of innovative medical devices and other therapeutics for equine
athletes and companion animals, announced today it has entered into
a definitive exclusive distribution services agreement with MWI
Animal Health, a leading distributor of animal health products and
services and a subsidiary of AmerisourceBergen.
MWI will inventory, market, and promote
PetVivo’s veterinary medical device, Spryng™ with OsteoCushion™
Technology, throughout the United States. Through its network of
distribution centers in key markets nationwide, MWI can support
efficient deliveries to communities nationwide.
"We are pleased with the commitment MWI has made
to PetVivo in the roll out of this new relationship that includes
the distribution of our lead product, Spryng. We view MWI as a
strategic partner that will allow PetVivo significant exposure to
and penetration in the US animal health market. This new
relationship will benefit the industry, the veterinarian who
provides the medical care, their patients and the pet owner alike,"
stated John Lai, Chief Executive Officer for PetVivo.
PetVivo’s innovative product, Spryng with
OsteoCushion Technology, is a veterinary medical device comprised
of millions of micronized hydrogel matrices, which are derived from
natural biocompatible components. OsteoCushion Technology provides
both reinforcing natural joint support to augment and reinforce
missing and/or damaged cartilage, as well as delivers natural
scaffolding to help address tissue defects. These attributes offer
a great solution to manage lameness and joint afflictions, such as
osteoarthritis, for companion animals in a simple in-clinic
administration.
“We continue to see tremendous innovation across
the animal health industry, including the emergence of novel
therapies and devices. We work closely with companies leading these
efforts to ensure veterinarians nationwide have access to the
latest products and services that have the potential to help pets
live longer and healthier lives,” said Steve Shell, president of
MWI Animal Health. “We are thrilled to work with PetVivo to provide
veterinarians with timely and reliable access to the company’s new
medical device.”
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of nineteen
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG™
with OsteoCushion™ technology, a veterinarian-administered,
intraarticular injection for the management of lameness and other
joint related afflictions, including osteoarthritis, in dogs and
horses, is currently available for commercial sale.
For more information about PetVivo Holdings,
Inc. and our revolutionary product, Spryng with OsteoCushion
Technology, please contact info1@petvivo.com or visit
https://petvivo.com/
CONTACT:
John Lai, CEOPetVivo Holdings, Inc.Email:
info1@petvivo.com(952) 405-6216
Forward-Looking commercial
Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements,
including the potential listing of the Company’s common stock on
Nasdaq, are based on information currently available the Company
and its current plans or expectations and are subject to a number
of uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2021 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Aug 2024 to Sep 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Sep 2023 to Sep 2024